At Regeneron, everything starts with the science
Regeneron was founded by physician scientists, and today, more than 20 years later, strong science remains at the heart of our capabilities and culture.
Through our original research we have discovered novel drug targets such as angiopoietins and neurotrophins, and we have developed product candidates to these targets as well as to others that have been validated by academic researchers or other pharmaceutical companies. We have pursued both novel and validated targets because we believe this is a strategy that balances risk and reward. We have also built broad discovery, development, and production platform technologies because we believe these are also essential to create a truly successful biotechnology company.
Using platform technologies created by Regeneron scientists, we have rapidly discovered and validated new targets and developed new product candidates.
- VelociGene® is a system for efficiently manipulating the mouse genome to investigate the function of unknown genes and validate clinical targets. More about VelociGene®
- VelociMouse® technology offers time and cost-saving advantages over other technologies used to create genetically modified mice for use as preclinical disease models.
- VelocImmune™ is a transgenic mouse technology that can generate a diversity of fully-human monoclonal antibodies to address clinically relevant targets of therapeutic interest. More about VelocImmune
- VelociMab™ is a platform for the rapid screening of antibodies and rapid generation of expression cell lines for antibodies and fusion proteins we call Traps.
- Trap is a fusion-protein technology that creates high affinity antibody-like molecules that trap specific extracellular signaling molecules such as cytokines and growth factors, blocking the activity of such molecules in certain disease settings. More about Traps
Regeneron employs more than 750 people in research and development functions, and over 300 of our employees have Ph.D. or M.D. degrees.